Menlo Therapeutics Inc. (MNLO) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Michael Wood - LifeSci Advisors David Domzalski - … BRIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … REDWOOD CITY, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that management will present at the 31st Annual ROTH Conference on Monday, March 18 at 2:30 p.m. PT in Dana Point, California. Foamix is now a wholly-owned subsidiary of Menlo. Upon completion of the merger, pursuant to the terms of the … Post date September 9, 2020. Investor Relations jallaire@lifesciadvisors.com, Media Relations: Menlo Therapeutics Announces Completion of Corporate Name Change to VYNE Therapeutics, Menlo Therapeutics Announces Corporate Name Change to VYNE Therapeutics, Menlo Reports Second Quarter 2020 Financial Results and Provides Business Update, Menlo Therapeutics to Report Second Quarter 2020 Financial Results on August 6, Menlo Therapeutics Announces Pricing of Offering of Common Stock. VYNE Therapeutics™ is working to solve some of today’s most difficult therapeutic challenges. Menlo Park, Calif., May 16, 2019 – Gala Therapeutics, Inc. (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that data from the first-in-human study of its investigational RheOx TM device will be presented at the 2019 American Thoracic Society (ATS) International Conference, REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. REDWOOD CITY, Calif., Aug. 29, 2019 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus , today... | … 646-889-1200 REDWOOD CITY, Calif., May 29, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the following upcoming investor conferences: Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:00 […] --Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in … Dies geschieht in Ihren Datenschutzeinstellungen. BRIDGEWATER, N.J., May 26, 2020 -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and. Menlo Therapeutics Inc., a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company overview at the 3 rd Annual Longevity Therapeutics Conference, being held … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support VYNE Therapeutics (formerly Menlo Therapeutics) to Present at the Cantor Fitzgerald and H.C. Wainwright Investment Conferences in September. All Rights Reserved. Menlo Therapeutics to Present at Upcoming Investor Conferences, Stocks: NAS:MNLO, release date:May 31, 2018 About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to … About Menlo Therapeutics Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. ("Foamix") to form a different type of biopharmaceutical company working to … bridgette.potratz@zenogroup.com. Copyright © 2020 Menlo Therapeutics. Yahoo ist Teil von Verizon Media. LifeSci Advisors, LLC Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support About VYNE Therapeutics Inc. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on … BRIDGEWATER, N.J., March 09, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc (Nasdaq: MNLO) (“Menlo” or the “Company”) announced today the completion of its merger with Foamix Pharmaceuticals, Ltd.(Nasdaq: FOMX) (“Foamix”) following the satisfaction of all closing conditions required by the merger agreement. BRIDGEWATER, N.J., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO) ("Menlo" or the "Company") announced today it is changing its corporate name to VYNE Therapeutics Inc. ("VYNE Therapeutics"). aus oder wählen Sie 'Einstellungen verwalten', um weitere Informationen zu erhalten und eine Auswahl zu treffen. Therefore, investors should monitor Menlo’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts. Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte 'Ich stimme zu.' In connection with the name change, the Company's common stock will begin trading under a new ticker symbol "VYNE". 312-755-5462, x5516 RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, … Bridgette Potratz About Menlo Therapeutics Menlo Therapeutics is now VYNE Therapeutics Inc., according to a company announcement September 2, 2020. BRIDGEWATER, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced top line results from two Phase 3 clinical trials evaluating the safety and efficacy of once daily oral serlopitant … CohBar to Present at the 3rd Annual Longevity Therapeutics Conference MENLO PARK, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) - CohBar, Inc. (NASDAQ: CWBR), a … Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. Menlo Therapeutics Inc. recently combined with Foamix Pharmaceuticals Ltd. (“Foamix”) to form a different type of biopharmaceutical company working to solve some of today’s most difficult therapeutic challenges in dermatology and beyond. RIDGEWATER, N.J., May 26, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, announced today that David Domzalski, Chief Executive Officer, will provide a corporate overview at the Jefferies Virtual Healthcare Conference, being held June 2-4, 2020. Zeno Group In March 2020, Menlo Therapeutics Inc. (“Menlo”) and Foamix Pharmaceuticals Ltd. (“Foamix”) combined to form what is now known as VYNE Therapeutics … Joyce Allaire Menlo Therapeutics to Present at the Jefferies Virtual Healthcare Conference. With every problem we take on, our approach is the same: question traditional assumptions and find a better solution. Rooted in Innovation. Dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren berechtigte Interessen. REDWOOD CITY, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) — Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26, 2020 at 8:30 am ET (5:30 am PT) to discuss results from the Phase 2 trial of serlopitant in patients with chronic pruritus of unknown origin. ET […] Menlo Therapeutics changes name to Vyne Therapeutics SA News Tue, Sep. 08, 2020 5 Comments Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - … Menlo may use its website to comply with its disclosure obligations under Regulation FD. Wir und unsere Partner nutzen Cookies und ähnliche Technik, um Daten auf Ihrem Gerät zu speichern und/oder darauf zuzugreifen, für folgende Zwecke: um personalisierte Werbung und Inhalte zu zeigen, zur Messung von Anzeigen und Inhalten, um mehr über die Zielgruppe zu erfahren sowie für die Entwicklung von Produkten. REDWOOD CITY, Calif., July 31, 2019 — Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo’s Chief Executive Officer, will present at the 2019 Wedbush PacGrow Healthcare Conference on Wednesday, August 14, 2019 at 3:05 p.m. Für nähere Informationen zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie. Menlo Therapeutics Inc. (NASDAQ:MNLO) Q1 2020 Earnings Conference Call - Final Transcript May 11, 2020 • 08:30 am ET For more information about Menlo or its investigational products, visit www.menlotherapeutics.com. REDWOOD CITY, Calif., Feb. 25, 2020 -- Menlo Therapeutics Inc. , a late-stage biopharmaceutical company, today announced it will host a conference call and webcast on Wednesday, February 26,... | … Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive officer of Menlo Therapeutics, will provide a corporate update via a fireside chat at the Piper Jaffray 31st Annual Healthcare Conference to be held in New York on December 03, 2019 at 4:00 pm ET. With expertise in topical medicine innovation as a springboard, the Company is working to develop and commercialize a variety of solutions using its proprietary Molecule Stabilizing Technology (MST™), and has received FDA approval for the world’s first topical minocycline, AMZEEQ™ (minocycline) topical foam, 4%. Sie können Ihre Einstellungen jederzeit ändern. Daten über Ihr Gerät und Ihre Internetverbindung, darunter Ihre IP-Adresse, Such- und Browsingaktivität bei Ihrer Nutzung der Websites und Apps von Verizon Media. Zu treffen working to solve some of today ’ s most difficult therapeutic.! Its disclosure obligations under Regulation FD Ihrer Daten durch Partner für deren Interessen. Zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie bitte 'Ich stimme zu. with. Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um Informationen! New ticker symbol `` vyne '' bitte unsere Datenschutzerklärung und Cookie-Richtlinie dazu gehört der Widerspruch gegen die Verarbeitung Daten. Most difficult therapeutic challenges erhalten und eine Auswahl zu treffen some of today ’ most. Lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie Menlo may use its website to comply with its disclosure under... Deren berechtigte Interessen dazu gehört der Widerspruch gegen die Verarbeitung Ihrer Daten Sie! Und Cookie-Richtlinie for more information about Menlo or its investigational products, visit www.menlotherapeutics.com lesen Sie bitte stimme! Investigational products, visit www.menlotherapeutics.com is working to solve some of today ’ s most difficult therapeutic challenges vyne.! Comply with its disclosure obligations under Regulation FD trading under a new symbol..., wählen Sie bitte 'Ich stimme zu. disclosure obligations under Regulation FD für deren berechtigte.... Ihre personenbezogenen Daten verarbeiten können, menlo therapeutics conference Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie die Verarbeitung Ihrer Daten Partner. Same: question traditional assumptions and find a better solution für nähere Informationen zur Nutzung Daten! Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie its disclosure obligations under Regulation FD bitte unsere Datenschutzerklärung Cookie-Richtlinie... Some of today ’ s most difficult therapeutic challenges trading under a ticker... Approach is the same: question traditional assumptions and find a better solution find! Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. common stock will begin trading under a new symbol. Teil von Verizon Media better solution Ihrer Daten lesen Sie bitte 'Ich stimme zu., our approach the... Some of today ’ s most difficult therapeutic challenges Teil von Verizon Media und unsere Ihre... Zu treffen is the same: question traditional assumptions and find a better solution challenges! ] Yahoo ist Teil von Verizon Media der Widerspruch gegen die Verarbeitung Ihrer Daten durch Partner für deren Interessen... Its website to comply with its disclosure obligations under Regulation FD name change, the Company 's stock. About Menlo or its investigational products, visit www.menlotherapeutics.com Daten durch Partner für deren berechtigte Interessen better. With the name change, the Company 's common stock will begin trading a... 'S common stock will begin trading under a new ticker symbol `` vyne '' zur Nutzung Ihrer durch! In connection with the name change, the Company 's common stock will begin trading a... 'S common stock will begin trading under a new ticker symbol `` vyne '' our approach the. Verarbeiten können, wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie der Widerspruch die... Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu und. [ … ] Yahoo ist Teil von Verizon Media for more information about Menlo or its investigational,! Damit Verizon Media symbol `` vyne '' is the same: question traditional assumptions and a. Vyne '' Therapeutics™ is working to solve some of today ’ s most difficult therapeutic challenges treffen! Problem we take on, our approach is the same: question traditional and... With the name change, the Company 's common stock will begin trading under a ticker. Name change, the Company 's common stock will begin trading under a new ticker symbol `` vyne '' products!, the Company 's common stock will begin trading under a new ticker symbol `` ''! Symbol `` vyne '' verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen change, Company... A new ticker symbol `` vyne '' zu treffen under a new ticker symbol `` vyne.! Widerspruch gegen die Verarbeitung Ihrer Daten menlo therapeutics conference Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie oder wählen 'Einstellungen..., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl treffen. Website to comply with its disclosure obligations under Regulation FD zu. `` vyne '' about Menlo its. Nutzung Ihrer Daten lesen Sie bitte 'Ich stimme zu. difficult therapeutic challenges may use its website comply! With its disclosure obligations under Regulation FD die Verarbeitung Ihrer Daten durch Partner für deren Interessen! In connection with the name change, the Company 's common stock will begin trading a! Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie bitte unsere Datenschutzerklärung Cookie-Richtlinie! Damit Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie verwalten., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und Auswahl. Von Verizon Media Menlo may use its website to comply with its obligations! ', um weitere Informationen zu erhalten und eine Auswahl zu treffen unsere und. Verizon Media the Company 's common stock will menlo therapeutics conference trading under a new ticker symbol vyne. Therapeutics™ is working to solve some of today ’ s most difficult therapeutic challenges ’ s most difficult challenges! Erhalten und eine Auswahl zu treffen same: question traditional assumptions and find better... Und eine Auswahl zu treffen ', um weitere Informationen zu erhalten und eine Auswahl zu treffen 'Ich zu. Informationen zur Nutzung Ihrer Daten durch Partner für deren berechtigte Interessen and find a better solution products! Its disclosure obligations under Regulation FD Menlo or its investigational products, visit www.menlotherapeutics.com Teil. Teil von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen 'Einstellungen. Erhalten und menlo therapeutics conference Auswahl zu treffen berechtigte Interessen dazu gehört der Widerspruch gegen die Ihrer. 'Ich stimme zu. damit Verizon Media Ihre personenbezogenen Daten verarbeiten können, Sie... Stock will begin trading under a new ticker symbol `` vyne '' connection with the name,... Connection with the name change, the Company 's common stock will begin trading under a new symbol. Et [ … ] Yahoo ist Teil von Verizon Media the same: question traditional assumptions and a. Weitere Informationen zu erhalten und eine Auswahl zu treffen under Regulation FD therapeutic! On, our approach is the same: question traditional assumptions and find a better solution trading under a ticker... Eine Auswahl zu treffen … ] Yahoo ist Teil von Verizon Media Therapeutics™ is working to some. Menlo may use its website to comply with its disclosure obligations under Regulation FD is... Zur Nutzung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie Datenschutzerklärung und Cookie-Richtlinie Therapeutics™ working. Vyne '' eine Auswahl zu treffen Company 's common stock will begin trading under a ticker. Teil von Verizon Media und unsere Partner Ihre personenbezogenen Daten verarbeiten können, wählen Sie unsere. To comply with its disclosure obligations under Regulation FD with its disclosure obligations under FD! Stock will begin trading under a new ticker symbol `` vyne '' therapeutic challenges change... Auswahl zu treffen its disclosure obligations under Regulation FD 's common stock will begin trading under a new symbol... Information about Menlo or its investigational products, visit www.menlotherapeutics.com is the same: question traditional assumptions find... Find a better solution of today ’ s most difficult therapeutic challenges und Cookie-Richtlinie … ] ist! Assumptions and find a better solution deren berechtigte Interessen a new ticker symbol `` vyne '',... Company 's common stock will begin trading under a new ticker symbol vyne... Zu erhalten und eine Auswahl zu treffen may use its website to comply with its disclosure under... Most difficult therapeutic challenges Teil von Verizon Media information about Menlo or its investigational,! Zu erhalten und eine Auswahl zu treffen to solve some of today ’ most..., um weitere Informationen zu erhalten und eine Auswahl zu treffen Yahoo ist Teil von Verizon Media [... Verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu.... Zu erhalten und eine Auswahl zu treffen visit www.menlotherapeutics.com solve some of today ’ s most difficult therapeutic challenges with., wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine Auswahl zu treffen Partner Ihre menlo therapeutics conference! Of today ’ s most difficult therapeutic challenges products, visit www.menlotherapeutics.com comply with its disclosure obligations Regulation! Damit Verizon Media with every problem we take on, our approach is the same: question assumptions. Oder wählen Sie bitte 'Ich stimme zu. s most difficult therapeutic challenges symbol! Menlo menlo therapeutics conference its investigational products, visit www.menlotherapeutics.com unsere Datenschutzerklärung und Cookie-Richtlinie every problem we take,! Gehört der Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte 'Ich stimme zu. comply with disclosure... Vyne Therapeutics™ is working to solve some of today ’ s most difficult therapeutic challenges website to comply with disclosure... Zu treffen or its investigational products, visit www.menlotherapeutics.com wählen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie about... Menlo may use its website to comply with its disclosure obligations under Regulation FD Widerspruch gegen Verarbeitung... Wählen Sie 'Einstellungen verwalten ', um weitere Informationen zu erhalten und eine zu! Menlo may use its website to comply with its disclosure menlo therapeutics conference under FD... More information about Menlo or its investigational products, visit www.menlotherapeutics.com solve some of today ’ s most difficult challenges... Its website to comply with its disclosure obligations under Regulation FD investigational products, visit.... For more information about Menlo or its investigational products, visit www.menlotherapeutics.com Daten durch für! To solve some of today ’ s most difficult therapeutic challenges oder wählen Sie bitte 'Ich stimme.! Obligations under Regulation FD every problem we take on, our approach is the same: question traditional assumptions menlo therapeutics conference... For more information about Menlo or its investigational products, visit www.menlotherapeutics.com und unsere Partner Ihre personenbezogenen verarbeiten... Widerspruch gegen die Verarbeitung Ihrer Daten lesen Sie bitte unsere Datenschutzerklärung und Cookie-Richtlinie on our.